The Global Fund to fight AIDS, TB and Malaria was created in 2002 when the world realized it was failing to respond adequately to the AIDS epidemic, TB and malaria.
- view as grid
- view as list
For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance.
This session will highlight how funding for HIV/AIDS has (and has not) strengthened health systems overall. Each panelist will address the question: Based on evidence collected so far, what conditions need to be present for HIV funding to strengthen health systems?
HIV epidemics among Men who have Sex with Men (MSM) are unfolding across Africa.
In the current context of global economic recession and contracting resources for HIV/AIDS world-wide, this session will tackle the following questions: whether new funding mechanisms can raise and secure necessary funds for global development, including health; whether policies currently pursued by other global financial actors such as the World Bank and the IMF are supportive of global health; whether disease-specific programmes are viable in the current economic climate; and what arguments HIV/AIDS activists can make to ensure that resources continue to be available for health programmes, including HIV/AIDS programmes.
Integration of services is a key challenge in the global response to the HIV and TB epidemics.
Despite years of prevention efforts, HIV incidence has been inadequately controlled and the HIV/AIDS epidemic remains a global public health crisis.
Recent guidelines are all recommending that HIV treatment be started at a higher CD4 count because of issues such as the ongoing damage caused by HIV itself, and prevention of transmission. Issues in long-term treatment, such as potential side effects, the development of resistance, the cost and sustainability of programmes in resource-poor settings, are some of the potential problems for such a strategy.
AIDS 2010: Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
An update of current state of microbicide development will be provided. Speakers will provide a state of microbicide development update, safety and efficacy data from CAPRISA 004 and implications of the CAPRISA 004 trial results for the microbicide and PrEP field.
HIV programs represent the first successful large-scale chronic disease program in resource-limited settings in history.